A simple blood test may reveal how ewing sarcoma responds to therapy
NCT ID NCT07725783
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This study tests whether changes in a blood protein called ProGRP can signal how well Ewing sarcoma is responding to treatment. Researchers will measure ProGRP levels in 100 newly diagnosed patients before, during, and after chemotherapy, then compare those levels with tumor size on scans. If ProGRP tracks with tumor changes, it could become a non-invasive way to monitor the disease. The blood test results are for research only and will not affect treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If ProGRP levels reliably reflect tumor response, doctors might one day use a simple blood test to monitor Ewing sarcoma treatment, reducing the need for frequent imaging.
- What could go wrong
- This is an early observational study, not a treatment trial. ProGRP may not correlate well with tumor changes, and results are for research only — they won't guide patient care during the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital, Beijing, Beijing 100044
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted radiation zaps childhood brain tumors in early trial
- New immunotherapy targets genetic flaw in rare childhood cancers
- Engineered immune cells take on Hard-to-Treat sarcomas
- Engineered immune cells take on Hard-to-Treat sarcomas
- Dietary change explored as cancer support strategy
- New drug combo aims to stall bone sarcoma in phase 2 trial